Preface.
1. Cancer epidemiology.
1.1 Cancer incidence, prevalence and mortality.
1.2 Childhood cancers.
1.3 Global epidemiology.
2. Histopathology of cancer.
2.1 Introduction.
2.2 Malignant, benign and normal (non-malignant) tissue.
2.3 Cell death.
3. Carcinogenesis, malignant transformation and
progression.
3.1 Introduction.
3.2 Chemical carcinogenesis.
4. Molecular biology of cancer: Oncogenes and tumour
suppressor genes.
4.1 Introduction.
4.2 Oncogenesis.
4.3 Tumour suppressor genes.
5. Tumour metastasis: A convergence of many theories.
5.1 Introduction.
5.2 Detachment and migration from the primary tumour.
5.3 Intravasation.
5.4 Transport.
5.5 Extravasation.
5.6 Growth of the metastatic tumour mass.
6. Health professionals in the treatment of cancer.
6.1 Introduction.
6.2 Pathology.
6.3 Radiology.
6.4 Role of the surgical oncologist.
6.5 Oncology pharmacy.
6.6 Oncology nursing.
6.7 The NHS Cancer Plan.
7. Principles of cancer chemotherapy.
7.1 Introduction.
7.2 Timing of chemotherapy.
7.3 Biomarkers and their uses.
7.4 Clinical assessment of biomarkers.
7.5 Pharmacogenetics and pharmacogenomics of cancer
chemotherapy.
8. Classic anticancer agents.
8.1 Introduction.
8.2 Alkylating agents.
8.3 Antimetabolites.
8.4 Agents derived from natural or semisynthetic products.
8.5 Hormonal anticancer agents.
8.6 Clinically used chemotherapy regimens.
9. The philosophy of cancer research.
9.1 Introduction.
9.2 Structure of cancer research organizations in the United
Kingdom.
9.3 Cancer research in the United States.
10. Novel anticancer agents.
10.1 Introduction.
10.2 Target validation.
10.3 Identification and optimization of lead drugs.
10.4 Preclinical pharmacology.
11. Clinical trials.
11.1 Introduction.
11.2 Evaluation of treatment response.
11.3 Assessment of vascularity and angiogenesis by nuclear
medicine technology.
12. Tumour hypoxia.
12.1 Introduction.
12.2 Bioreductive drugs.
12.3 Inhibitors of HIF-1 and HIF-1-regulated genes.
13. Antiangiogenic and antivascular agents.
13.1 History of angiogenesis as a therapeutic target.
13.2 Anti-angiogenic drug targets.
13.3 The return of thalidomide.
13.4 Monoclonal antibodies as anti-angiogenic agents.
13.5 The hollow fibre assay as a drug screen for
anti-angiogenic
drugs.
13.6 Vascular disrupting agents.
14. Tyrosine kinase inhibitors.
14.1 Introduction.
14.2 Tyrosine kinase inhibitors targeting angiogenesis.
14.3 Non-receptor tyrosine kinase inhibitors.
15. Ras inhibitors.
16. Inhibitors of the Akt PKB pathway.
17. Targeting stress proteins: HSP90 inhibitors.
18. The proteasome.
18.1 Introduction.
18.2 The proteasome as a target for novel drug strategies.
18.3 Ubiquitylation as a target.
19. Checkpoint protein kinases as novel targets - mammalian
target of rapamycin (mTOR).
19.1 Mammalian target of rapamycin.
19.2 Structure and activation of mTOR.
19.3 Novel anticancer agents targeting mTOR.
20. Telomerase.
21. Histone deacetylase: an epigenetic drug target.
21.1 Introduction.
21.2 HDAC and DNA packaging.
21.3 HDAC inhibitors.
22. Pharmaceutical problems in cancer chemotherapy.
22.1 Manifestation of toxicity.
22.2 Regimen-related toxicity.
22.3 Secondary malignancies.
22.4 Drug resistance.
22.5 Pharmaceutical complications.
22.6 Phlebitis and venous irritation.
22.7 Health and safety.
22.8 National guidance on the safe administration of
intrathecal
chemotherapy.
23. Oncology pharmacy at home and abroad.
24. Practice exam questions.
25. Bibliography and further reading.
Index.
Rachel Airley, School of Pharmacy and Pharmaceutical Sciences, University of Huddersfield, UK.
"True to the title, the strength of the book is the discussion
of
chemotherapies themselves. The classical anticancer drugs are
well
dealt with in Chapter 8 with good background information and
plenty
of chemical structures and figures explaining mechanisms".
(Australian Biochemist , 1 April 2011)
"A useful addition to stand beside standard sources."
(Pharmaceutical Journal, December 2009)
 |
Ask a Question About this Product More... |
|
